Last Updated : March 18, 2024
Details
FilesGeneric Name:
avatrombopag
Project Status:
Active
Therapeutic Area:
Chronic immune thrombocytopenia (ITP)
Manufacturer:
Sobi Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Doptelet
Project Line:
Reimbursement Review
Project Number:
SR0721-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | 23-Dec-21 |
---|---|
Call for patient/clinician input closed | 18-Feb-22 |
Clarification: - Patient input submission received from the Platelet Disorder Support Association | |
Submission received | 03-Feb-22 |
Submission accepted | 17-Feb-22 |
Review initiated | 18-Feb-22 |
Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted | |
Draft CADTH review report(s) provided to sponsor for comment | 06-Sep-23 |
Deadline for sponsors comments | 15-Sep-23 |
CADTH review report(s) and responses to comments provided to sponsor | 13-Oct-23 |
Expert committee meeting (initial) | 25-Oct-23 |
Draft recommendation issued to sponsor | 14-Nov-23 |
Draft recommendation posted for stakeholder feedback | 23-Nov-23 |
End of feedback period | 07-Dec-23 |
Clarification: - Reconsideration: major revisions requested by sponsor | |
Expert committee meeting | 24-Apr-24 |
Files
Last Updated : March 18, 2024